Myriad Genetics Expands Research Collaborations for Breast Cancer Testing
Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic testing and precision medicine, has recently embarked on a series of important research collaborations aimed at studying the application of molecular residual disease (MRD) testing in breast cancer. These initiatives leverage Myriad’s innovative Precise MRD test to advance the understanding and treatment of this prevalent disease.
Details of the Research Collaborations
The collaborations encompass several significant studies, each focusing on different aspects of breast cancer and ctDNA (circulating tumor DNA) testing. One notable project evaluates whether ctDNA levels can predict the response to treatments such as pembrolizumab combined with hormonal therapy in patients diagnosed with HR-positive inflammatory breast cancer. This study is led by Bora Lim, MD, at The University of Texas MD Anderson Cancer Center.
Correlating ctDNA with Nodal Involvement
Another collaborative effort directed by Anna Weiss, MD, at The University of Rochester Medical Center, seeks to determine the relationship between ctDNA levels and lymph node involvement in newly diagnosed HR-positive breast cancer patients. The findings may influence surgical decisions and improve outcomes for patients.
MONITOR-breast Study Overview
A larger, multicenter prospective study known as MONITOR-breast aims to assess the relationship between ctDNA levels and both neoadjuvant and adjuvant therapies for breast cancer patients across various subtypes. Involving around 650 participants, this study will evaluate the prognostic capabilities of ctDNA as well as its potential to detect recurrences earlier than current imaging standards.
Innovative Approaches in Therapy Guidance
Additionally, the JBCRG-C11 (CREA) study focuses on the effectiveness of maintaining complete response with trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive breast cancer. This research tests whether ctDNA can provide optimal therapeutic guidance, led by Yoichi Naito, MD, at the National Cancer Center Hospital East in Japan.
Community Oncology Insights
In collaboration with Aptitude Health, another research project is assessing ctDNA levels in high-risk breast cancer patients at diagnosis and during treatment, including follow-ups after surgery and in community oncology settings. This initiative aims to understand better the role of ctDNA in standard cancer care practices.
Advancements in MRD Testing
The challenge of detecting ctDNA in breast cancer, which typically presents lower ctDNA levels compared to other cancers, has led Myriad Genetics to focus on refining its Precise MRD test. According to Dale Muzzey, chief scientific officer at Myriad Genetics, this test can track up to 1,000 tumor-specific variants through whole-genome sequencing, thus improving sensitivity and accuracy in monitoring patients.
Myriad’s commitment to developing the Precise MRD test aims to fulfill the needs of cancer patients, academic researchers, and biopharmaceutical companies. This vision includes maintaining ongoing partnerships and expanding the application of MRD testing in clinical settings.
About Myriad Genetics
Myriad Genetics stands at the forefront of genetic testing and precision medicine. The company is devoted to enhancing health outcomes through its innovative tests, which identify the risk of disease development and progression. These insights guide treatment decisions across various medical fields, enabling healthcare practitioners to provide better care while also reducing overall costs.
To learn more about Myriad’s offerings and research initiatives, visit their official website.
Frequently Asked Questions
What is MRD testing?
MRD testing refers to the detection of molecular residual disease, particularly assessing ctDNA levels to monitor the presence of cancer after treatment.
How does Myriad’s Precise MRD test work?
The Precise MRD test utilizes whole-genome sequencing to track tumor-specific variants, providing high sensitivity for ctDNA detection.
What are the goals of the recent collaborations announced by Myriad?
The collaborations aim to enhance understanding of ctDNA in breast cancer treatment, improve patient outcomes, and validate the clinical application of MRD tests.
Who leads the various studies involving Myriad's MRD test?
Various prominent researchers and institutions, such as MD Anderson Cancer Center and the National Cancer Center Hospital, are leading the studies.
Why is ctDNA testing more challenging in breast cancer?
Breast cancer often exhibits lower levels of ctDNA in circulation compared to other cancers, complicating the detection process.
